Why your weight loss on Mounjaro feels very slow — and what actually helps

Is very slow early progress on Mounjaro actually a problem?

Most people who start tirzepatide lose very little weight in weeks one to four, and that is not a warning sign. The 2.5 mg pen your prescriber begins with is calibrated around tolerability, not fat loss. Its job is to introduce the medicine gently so that side effects like nausea stay manageable. Expecting the scales to move dramatically at this stage is like expecting a car to hit motorway speed from idle.

What the clinical evidence shows is a slow build. In SURMOUNT-1, published in the New England Journal of Medicine, participants who reached 15 mg over the 72-week trial period lost around 20 to 21% of their body weight on average, but the trajectory was not linear. Loss typically accelerated after the first few dose increases. If you are still on 2.5 mg or 5 mg, comparing your progress to someone at 10 mg or 12.5 mg is comparing different points on the same journey. You can read more about the general timeline on our page covering how long Mounjaro takes to work.

That said, some people do hit a genuine plateau partway through treatment even at higher doses. A plateau is not the same as failure, but it is worth understanding the specific reasons it can happen.

What biological and lifestyle factors slow Mounjaro's effect?

Several things can dampen the weight-loss response to tirzepatide without meaning the medicine is not working. Sleep is one of the least-discussed. Short or poor-quality sleep raises cortisol and ghrelin, two hormones that drive appetite and fat storage. Tirzepatide acts on appetite pathways, but it cannot fully override a body primed by sleep deprivation to hold onto weight. Chronic stress has a similar cortisol-driven effect.

Fluid retention is another source of confusion. Your body can hold two to three kilograms of water at any given time depending on salt intake, the menstrual cycle, exercise and medication. The scales can stay flat for a fortnight while fat is actively being lost. Measuring waist circumference alongside weight gives a fuller picture and is often more reassuring.

Diet composition matters too. Tirzepatide reduces appetite significantly, but if the foods eaten during a reduced-appetite window are energy-dense, refined and low in protein, the calorie deficit shrinks quickly. Protein adequacy is particularly important on GLP-1 and dual-agonist treatment: without enough, some of the weight lost comes from muscle rather than fat. The NHS tirzepatide guidance recommends taking Mounjaro alongside a reduced-calorie diet and increased physical activity, precisely because the medicine works best as part of a wider approach rather than in isolation.

Some prescription medicines, including certain antidepressants, antipsychotics, corticosteroids and antihypertensives, can independently promote weight gain or blunt loss. If you started or changed any other medication around the time progress slowed, mention it to your prescriber. It is a straightforward conversation that can change the plan.

Could the dose just be too low for where you are now?

Quite possibly, yes. Tirzepatide is licensed in the UK at six strengths (2.5, 5, 7.5, 10, 12.5 and 15 mg) and the clinical evidence is clear that higher doses produce greater average weight loss. If your progress has slowed and you have been on the same dose for eight weeks or more without a clinical review, that is worth raising with your prescriber. A dose increase is not automatic: your prescriber needs to weigh up how well you are tolerating the current level before stepping up.

This is why ongoing clinical oversight matters. Our page on what to expect from weight loss on Mounjaro covers the dose-response relationship in more detail. The key point is that very slow progress at a low dose does not predict what will happen at a higher one. Many people find their results shift markedly once they reach 7.5 mg or above.

If you are sourcing treatment privately, make sure your provider reviews your progress before every repeat, not just at the start. That review is when dose adjustments are clinically justified and when any safety questions around increasing the dose are addressed. Keeping your pen in the fridge door and injecting on the same day each week makes it easier to track your pattern and gives your prescriber consistent information to work from.

When should very slow weight loss prompt a clinical conversation?

The NICE appraisal of tirzepatide (TA1026) notes that if less than 5% body weight has been lost after six months at the highest tolerated dose, continuing treatment should be reviewed. That is a clinical threshold, not a personal one, and our page on why weight loss on Mounjaro can feel slower than expected explains the practical reasons this threshold is so often misapplied. The relevant question is whether your dose has been properly titrated, whether there are modifiable factors at play, and whether the 5% threshold is being applied to the right phase of treatment.

If you are at a plateau and unsure whether to push for a dose increase, ask for advice before deciding anything yourself. Changing your dose schedule without clinical input is not safe. Your prescriber can look at your full picture (weight history, current dose, side effects, other medications) and make a recommendation based on evidence, not guesswork.

For those who feel their progress has stalled entirely rather than just slowed, our page on no weight loss on Mounjaro covers the next layer of investigation. And if you are wondering whether the medicine is working at all in the early weeks, the experiences covered on week one and week three pages offer useful context for those earlier stages.

If you have not yet started treatment and are weighing up your options, you can check your eligibility with our prescribers, no waiting list, no referral needed, and your consultation is reviewed the same day by a real clinician.